{"filing":{"accession_number":"0001437749-26-026275","cik":"0001533040","ticker":"PHIO","company_name":"Phio Pharmaceuticals Corp.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"phio20260519_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1533040/000143774926026275/phio20260519_8k.htm"},"events":[{"id":25750,"run_id":23370,"accession_number":"0001437749-26-026275","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard quarterly earnings release for the period ended June 30, 2026, disclosing financial results including R\u0026D expenses ($3.1M for Q2 2026 vs. $1.1M for Q2 2025), G\u0026A expenses ($1.2M vs. $1.2M), and net loss ($4.1M vs. $2.2M). The filing includes consolidated statements of operations and balance sheets, along with a business update on the lead clinical candidate PH-762. The Item 2.02 disclosure and attached press release (Exhibit 99.1) are characteristic of an earnings_release event.","company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26661,"accession_number":"0001437749-26-026275","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for the period ended June 30, 2026, disclosing financial results including R\u0026D expenses ($3.1M for Q2 2026 vs. $1.1M for Q2 2025), G\u0026A expenses ($1.2M vs. $1.2M), and net loss ($4.1M vs. $2.2M). The filing includes consolidated statements of operations and balance sheets, along with a business update on the lead clinical candidate PH-762. The Item 2.02 disclosure and attached press release (Exhibit 99.1) are characteristic of an earnings_release event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:31:01.928283+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26661,"accession_number":"0001437749-26-026275","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for the period ended June 30, 2026, disclosing financial results including R\u0026D expenses ($3.1M for Q2 2026 vs. $1.1M for Q2 2025), G\u0026A expenses ($1.2M vs. $1.2M), and net loss ($4.1M vs. $2.2M). The filing includes consolidated statements of operations and balance sheets, along with a business update on the lead clinical candidate PH-762. The Item 2.02 disclosure and attached press release (Exhibit 99.1) are characteristic of an earnings_release event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:31:01.928283+00:00","company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","filing_date":"2026-08-06"}]}